Last Updated 31 December 2013
With approximately 5.3 million patients diagnosed in the seven major pharmaceutical markets, epilepsy is a common, debilitating neurological condition that affects patients’ quality of life and imparts a social and economic burden on patients and their families, as well as healthcare institutions. Despite the availability of numerous established first-, second-, and third-generation antiepileptic drugs (AEDs)—many of which are, or are soon to be, generically available—considerable unmet need remains for effective treatment alternatives for 20-30% of drug-treated patients with refractory epilepsy who do not respond to current therapies. Ongoing efforts to better understand the basic science of epilepsy and seizures could uncover promising new targets and biomarkers to facilitate drug development in the future, but the near-term impact of such efforts on epilepsy treatment will be limited.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.
Primary research: 27 country-specific interviews with adult and pediatric neurologists who specialize in epilepsy.
Epidemiology: Diagnosed and drug-treated prevalence of epilepsy; diagnosed prevalence of epilepsy segmented by seizure type (partial-onset and generalized-onset) and age; drug-treated prevalent cases with drug-resistant epilepsy.
Emerging therapies: Phase II: 8 drugs; Phase III: 6 drugs; preregistration and registration: 1 drug. Coverage of 10 select preclinical and Phase I products.
Market forecast features: Using market research, primary research with key opinion leaders, and our proprietary forecasting model, we provide an in-depth examination of current and future epilepsy drug-treatment trends and market performance over a ten-year forecast period (2012-2022).